PATENT CLAIM ANALYSIS

Application Number: 15992957
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-04
Patent Classification: ["514", "427000"]

Abstract:
The present invention provides a therapeutic compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of HIV infection or combination therapy of HIV-1 protease inhibitors (PIs) and/or reverse transcriptase inhibitors (nRTIs) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.

Claim (Index 44):
A pharmaceutical composition comprising:\n i) a compound of formula (I) wherein the compound of formula (I) is present in an amount between about 1 mg to about 500 mg; and\n ii) a second therapeutic agent, \n wherein the second therapeutic agent is selected from the group consisting of an agent used to control blood glucose levels, an agent used to control lipid levels, an antioxidant, an appetite suppressing agent, an anti-obesity agent, an antibiotic, a probiotic, and an anti-inflammatory agent.

Metadata:
- Claim Count in Document: 86.0
- Percentile: 93.0
- Lexical Diversity: 1.23404
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15345035', '13978791', '12239708', '12239697', '10969463']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7673531539802363
- 35 USC 102 Novelty (BERT): 0.5417966383596481
- Combined Prediction Score: 0.7447975024181775
- Mean Citation Score: 292.809004
- Max Citation Score: 415.3839
- Similarity Product: 271.2169405333936

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test